Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Proqr Therapeutics
(NQ:
PRQR
)
2.100
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Proqr Therapeutics
< Previous
1
2
3
4
Next >
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 12, 2024
PRQR stock results show that ProQR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
ProQR Announces Second Quarter 2024 Operating and Financial Results
August 08, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 18, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces First Quarter 2024 Operating and Financial Results
May 09, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
4 Analysts Have This to Say About ProQR Therapeutics
August 04, 2023
Via
Benzinga
Analyst Ratings for ProQR Therapeutics
May 17, 2023
Via
Benzinga
Recap: ProQR Therapeutics Q1 Earnings
May 16, 2023
Via
Benzinga
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
May 08, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 23, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
April 22, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
April 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Year End 2023 Operating and Financial Results
March 13, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
February 15, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
January 19, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 18, 2024
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the...
Via
Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan...
Via
Benzinga
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
January 05, 2024
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
US Stocks Lower; Dow Falls Over 50 Points
November 27, 2023
U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday. Following the market opening Monday, the Dow traded down 0.18% to 35,328.05 while the NASDAQ fell 0.13%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
November 08, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces Second Quarter 2023 Operating and Financial Results
August 03, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
August 01, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
July 06, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR Announces First Quarter 2023 Operating and Financial Results
May 16, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
May 09, 2023
From
ProQR Therapeutics N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.